• 2016
    Apr
    13
    George Thomas

    "Inhibitors synergize to promote tumor inhibition in renal cell carcinoma"

    The intracytoplasmic tyrosine kinase Src serves both as a conduit and a regulator for multiple processes required for the proliferation and survival cancer cells. In some cancers, Src engages with receptor tyrosine kinases to mediate downstream signaling and in other cancers, it regulates gene expression. Src therefore represents a viable oncologic target.
    Read More
  • 2016
    Apr
    13
    tn-ohsu

    "Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma"

    Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist.
    Read More
  • 2016
    Apr
    13
    tn-ohsu

    KDL presents poster at AMP meeting. "NGS Library Preparation Directly from FFPE Tissue without DNA Purification"

    The quality of next-generation sequencing (NGS) results is critically dependent on the input material. Unfortunately, many biopsy specimens submitted for sequencing contain too little tissue to support DNA extraction, quantification and NGS library preparation. Yields from commercially available DNA extraction kits vary and DNA losses are inevitable during protease digestion and subsequent purification. We tested a novel research approach that allows amplicon-based NGS libraries to be prepared directly from pieces of formalin-fixed, paraffin-embedded (FFPE) tissue.
    Read More
Page:
Innovations in Testing
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More